Troybodies with specificity for APC (IgD and MHC class II) have been shown to improve T cell activation in vitro and in vivo. However, these Abs are for various reasons, not optimal for in vivo function. The project wants to extend th e Troybody strategy by making Troybodies with specificity for cell surface receptors on dendritic cells (DC) that are involved in innate immunity and induction of DC maturation. The project will also like to induce powerful CD8+ cytotoxic T cell responses by incorporation of MHC class I restricted T cell epitopes into loops of Troybodies. These novel Troybodies, designed to induce protection against cancer and infectious disease, will be thoroughly tested in in vitro and in vivo experiments and furthermore tested in a mouse tumor model system.